# Paliperidone

## Invega inj 100mg (=156mg)

| TAH Drug Code      | [IINV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IINV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Acute & maintenance treatment of schizophrenia in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen, adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Hypersensitivity to paliperidone or risperidone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Cerebrovascular events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM, wt gain, hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures, dysphagia, suicide, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions, somnolence/sedation, dizziness, akathisia & extrapyramidal disorder.                                                                                                                              |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## INVEGA inj 150mg (=234mg)

##### 臨採

| TAH Drug Code      | [IINV2](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IINV2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Acute & maintenance treatment of schizophrenia in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Initial: 234 mg on treatment day 1 followed by 156 mg 1 week later with both doses administered in the deltoid muscle. The second dose may be administered 4 days before or after the weekly time point. Maintenance: Following the 1-week initiation regimen, adjust the dose based on response and tolerability and begin a maintenance dose of 78 to 234 mg every month administered in either the deltoid or gluteal muscle (the 39 mg dose was not studied in schizoaffective disorder trials). The monthly maintenance dose may be administered 7 days before or after the monthly time point. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to paliperidone or risperidone.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Cerebrovascular events including stroke. Neuroleptic malignant syndrome, QT prolongation, tardive dyskinesia, hyperglycemia & DM, wt gain, hyperprolactinemia. Orthostatic hypotension & syncope. Leukopenia, neutropenia & agranulocytosis. Cognitive & motor impairment. Seizures, dysphagia, suicide, priapism, TTP. Disruption of body temp regulation. Antiemetic effect. Inj site reactions, somnolence/sedation, dizziness, akathisia & extrapyramidal disorder.                                                                                                                              |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

## Invega 3mg extended release

| TAH Drug Code      | [OINV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OINV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of schizophrenia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | Schizophrenia: Adults: 3-12mg QD. When the dose >6 mg/day, increased by 3 mg/day at intervals of more than 5 days. maximum: 12mg/day. 12-17 years old: initial dose: 3mg QD. The dose should be increased by 3 mg/day at intervals of more than 5 days. maximum dose:<51kg:6mg/day; >=51kg:12mg/day Schizoaffective Disorder: 6mg QD, increase by 3 mg/day at intervals of more than 4 days. maximum: 12mg/day.                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Hypersensitivity to risperidone. Congenital long QT syndrome, cardiac arrhythmias. Pre-existing severe GI narrowing. Lactation.                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Adverse Effects    | Cardiac disturbances, arrhythmia, GI disturbances, upper abdominal pain, extrapyramidal disorder, weight increase. Rarely edema, hypersensitivity reactions, dystonia, hypotension, venous thromboembolism. Cardiovascular: Tachycardia (16% geriatric ) Endocrine metabolic: Hyperprolactinemia (geriatric, 45% to 49% ), Weight gain (4% to 9% ) Gastrointestinal: Constipation (4% to 5% ), Indigestion (5% to 6% ) Neurologic: Akathisia (3% to 10% ), Extrapyramidal disease (2% to 20% ), Somnolence (6% to 12% ) Respiratory: Nasopharyngitis (2% to 5% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

